country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-181558

Copy Link Print Information

Anticancer agent 303

Anticancer agent 303 is a selective, orally active anticancer agent belonging to the pyrazolopyridine derivatives. Anticancer agent 303 exhibits low cytotoxicity to healthy cells, with a selective window of approximately 2-fold between cancer cells and healthy cells. Anticancer agent 303 produces detectable systemic exposure in mice following intraperitoneal or oral administration. Anticancer agent 303 effectively inhibits the proliferation of prostate cancer and breast cancer cells.

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

화학식: C₂₇H₃₀N₆O₂
분자량:470.57

보관:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (274 KB)

Anticancer agent 303 Chemical Structure

사이즈

가격

재고

수량

Amount: USD 0.00

* 장바구니에 담기 전 물품의 수량을 선택해 주십시오.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- 제품 설명
- In Vitro
- Parmacokinetics
- In Vivo
Chemical Information
순도&문서
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

제품 설명

In Vitro

Anticancer agent 303 (compound 17) (5 μM; 72 h) inhibits the viability of PC-3, MCF-7 and HUVEC cells, with mean IC₅₀ values of 4.8 μM, 3.9 μM and 8.7 μM, respectively^[1].
Anticancer agent 303 (5 μM; 1-24 h) accumulates in PC-3 cells in a time-dependent manner, reaching a level of 245.8 ng/40,000 cells (104.5% of the initial administered dose) after 24 h of treatment at 5 μM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay^[1]

Cell Line:

human prostate adenocarcinoma PC-3 cells
Concentration:

5 μM
Incubation Time:

72 h
Result:

Reduced PC-3 cell viability to 36% relative to DMSO control.
Exhibited an average IC₅₀ of 4.8 ± 0.9 μM.

Cell Cytotoxicity Assay^[1]

Cell Line:

human breast adenocarcinoma MCF-7 cells
Concentration:

5 μM
Incubation Time:

72 h
Result:

Reduced MCF-7 cell viability to 33% relative to DMSO control.
Exhibited an average IC₅₀ of 3.9 ± 0.9 μM.

Parmacokinetics

Species	Dose	Route	C_max	T_max	T_1/2	AUC_0-t	AUC_0-∞	Bioavailability
Mice^[1]	4 mg/kg	i.p.	372.2 ng/mL	4.8 h	14.4 h	5847.1 ng·h/mL	8721.3 ng·h/mL	/
Mice^[1]	8 mg/kg	p.o.	199.0 ng/mL	6.5 h	16.3 h	3338.0 ng·h/mL	5299.1 ng·h/mL	29.13 %

In Vivo

Anticancer agent 303 (compound 17) achieves systemic exposure in mice via intraperitoneal (i.p.) and oral (p.o.) administration. Intraperitoneal injection yields higher systemic exposure than oral administration, as indicated by increased Cmax and AUC, and has a shorter time to peak concentration (Tmax), while the elimination half-lives of the two administration routes are similar. In addition, the dose-normalized relative oral bioavailability of Anticancer agent 303 is 29.13%^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

분자량 470.57
화학식 C₂₇H₃₀N₆O₂
SMILES

O=C(NC1=CC=CC=C1)NC2=CC(OCCNC3CCCCC3)=C4C(N(C5=CC=CC=C5)N=C4)=N2
선적

Room temperature in continental US; may vary elsewhere.
보관

Please store the product under the recommended conditions in the Certificate of Analysis.

순도&문서

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (274 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Georgiou M, et al. Optimization of Pyrazolo[3,4‑b]pyridine Analogues: Synthesis, In Vitro Anticancer Evaluation and In Vivo Pharmacokinetics. ACS Omega. 2026;11(5):8479-8495. Published 2026 Jan 24. [Content Brief]

Calculators

몰농도 계산기

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

농도 희석 계산기

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

MOQ

Minimum order quantity

100 mg

견적 받기 해외재고보유

Other size

견적 받기